iSpecimen Inc. filings document material events, governance matters, capital-structure changes, and reporting status for the company’s Nasdaq-listed common stock. Recent 8-K disclosures cover the completed 1-for-40 reverse stock split, related certificate amendments, Regulation FD press-release exhibits, shareholder meeting adjournments, and board composition changes.
The company’s regulatory record also includes emerging growth company disclosures and a Rule 12b-25 notice tied to its annual report filing process. These filings provide formal records of iSpecimen’s public-company obligations alongside its biospecimen marketplace operations.
iSpecimen Inc. entered into a Settlement Agreement and Mutual Release with WestPark Capital, Inc. on August 6, 2026 to resolve all disputes, including an arbitration in which WestPark had sought $269,999.91 plus interest, fees, and costs. Under the agreement, iSpecimen paid WestPark $97,500 in full satisfaction of all claims, and WestPark dismissed the arbitration with prejudice, with each party bearing its own fees and costs. The parties granted each other a mutual general release, agreed to terminate the prior engagement agreements in their entirety (including any tail fee and right of first refusal), and accepted mutual confidentiality obligations and New York governing law with binding JAMS arbitration for disputes. iSpecimen expects to record the $97,500 as a charge in the quarter ending September 30, 2026.
iSpecimen Inc. entered placement agency and securities purchase agreements and completed a “reasonable best efforts” public offering of common stock and pre-funded warrants for an aggregate purchase price of $5,000,000 (or $5,000,285 assuming full exercise of the pre-funded warrants). The company issued 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 shares of common stock. The securities were sold under an effective registration statement on Form S-1.
The public offering price was $1.30 per share of common stock and $1.2999 per pre-funded warrant, with a $0.0001 per share exercise price on each pre-funded warrant. E.F. Hutton & Co. acted as exclusive placement agent, receiving a cash fee of 4.0% of aggregate gross proceeds plus a 1% non-accountable expense allowance and reimbursement of certain expenses and legal fees. iSpecimen plans to use the proceeds to repay outstanding liabilities, fund potential acquisitions or investments in businesses, products and technologies, support marketing and advertising services, and for general working capital.
iSpecimen Inc. is conducting a best-efforts primary offering of common stock and pre-funded warrants. The company is offering 996,231 shares of common stock at a public offering price of $1.30 per share, for up to $5,000,000.00 of shares and/or pre-funded warrants. Each pre-funded warrant is sold at $1.2999 and is exercisable into one share of common stock at $0.0001 per share, subject to a 4.99% beneficial ownership cap (electively raisable to 9.99% on 61 days’ notice).
Gross proceeds at the maximum share amount are $4,999,998.90, with placement agent fees of $199,999.96 and estimated proceeds before expenses of $4,799,998.94. Common shares outstanding were 1,522,359 as of August 5, 2026 and would increase to up to 5,368,512 shares if all pre-funded warrants from this offering are exercised. The stock trades on Nasdaq under the symbol ISPC, with a closing price of $1.92 per share on August 5, 2026.
The company reports a history of losses, including 2025 revenue of $1,928,998 and a net loss of $10,487,532, and an accumulated deficit of $84,625,370 as of March 31, 2026. Audited financial statements include a going concern explanatory paragraph, and management discloses a material weakness in internal control over financial reporting related to sales tax processes. Net proceeds are intended for fees and expenses, debt repayment, potential asset or business acquisitions, marketing and advertising (including up to $1,100,000 to IR Agency LLC), and general corporate and working capital purposes.
iSpecimen Inc. is pursuing a primary, best‑efforts equity offering of up to 2,092,050 shares of common stock, Pre‑Funded Warrants to purchase up to 2,092,050 shares, and up to 2,092,050 underlying shares, for aggregate gross proceeds of up to $5,000,000. The assumed price is $2.39 per Share, matching the July 14, 2026 Nasdaq close.
Common stock outstanding was 1,522,359 shares as of July 14, 2026 and would increase to up to 3,614,409 shares if the full offering is sold and all Pre‑Funded Warrants are exercised. Each Pre‑Funded Warrant costs $2.3899, is exercisable at $0.0001 per share, and is subject to 4.99% (or 9.99% on notice) beneficial‑ownership caps.
Assuming all Shares are sold and no Pre‑Funded Warrants are issued, net proceeds are estimated at approximately $4,680,000, to be used for fees and expenses, repayment of outstanding debt, potential asset or business acquisitions, marketing and advertising (including up to $1,100,000 for IR Agency LLC), and general corporate and working capital needs. For 2025, revenue was $1,928,998 with a net loss of $10,487,532; for the quarter ended March 31, 2026, revenue was $156,009 and net loss $2,275,221. As of March 31, 2026, cash was $2,818,989, working capital was negative $2,115,634, and the company reported substantial doubt about its ability to continue as a going concern.
iSpecimen Inc. completed Milestone 3 in its digital transformation program powered by SalesStack Solutions on July 9, 2026. Under Section 3.1 of the Definitive Software Purchase and Services Agreement with Sales Stack Solutions Corp., the company made a $700,000 payment upon completion.
Milestone 3 delivers additional marketplace features, a broader geographic rollout, and deeper integrations with partner ecosystems, building on the system integration and marketplace activation delivered in Milestone 2. The company had previously disclosed the completion of Milestones 1 and 2 under the same agreement.
iSpecimen Inc. has filed an amended S-1 to register up to 1,515,152 shares of common stock, up to 1,515,152 pre-funded warrants, and 1,515,152 shares issuable upon warrant exercise in a best-efforts offering capped at $4,000,000.00.
The assumed price is $2.64 per share, matching the July 2, 2026 Nasdaq close for ISPC, with each pre-funded warrant priced at $2.6399 and carrying a $0.0001 exercise price. If all shares are sold, net proceeds are estimated at about $3.72M, earmarked for fees and expenses, non‑interest‑bearing outstanding liabilities, up to $700,000 for potential acquisitions, up to $1,000,000 for marketing with IR Agency LLC, and general working capital.
The company reverse‑split its stock 1‑for‑40 in April 2026 and had 1,522,359 shares outstanding as of July 2, 2026, rising to a maximum of 3,440,599 shares if the offering and warrant exercises are fully completed. iSpecimen’s 2025 revenue was $1,928,998 with a net loss of $10,487,532; Q1 2026 revenue was $156,009 with a net loss of $2,275,221. As of March 31, 2026, cash was $2,818,989 and working capital was negative $2,115,634, and auditors highlighted substantial doubt about the company’s ability to continue as a going concern.
iSpecimen Inc. is registering up to 1,544,402 shares of common stock and related pre-funded warrants in a best-efforts offering. At an assumed price of $2.59 per share, the potential raise is up to $4.0 million, with common shares outstanding rising from 1,437,157 to as many as 2,981,559.
The company plans to use net proceeds for placement agent fees, debt repayment, potential acquisitions, up to $1.0 million of marketing and advertising (including services from IR Agency LLC), and general working capital. iSpecimen operates an online biospecimen marketplace but remains loss-making, with a going concern warning, an accumulated deficit of $84.6 million, limited cash of $2.8 million, and a working capital deficit.
iSpecimen Inc. registers 488,290 shares of Common Stock for resale by selling stockholders. This prospectus covers up to 488,290 shares of common stock consisting of 85,202 Shares issued in the May 2026 Private Placement and 403,088 Warrant Shares issuable upon exercise of Pre-Funded Warrants, to be offered and resold from time to time by the selling stockholders. The Company will not receive proceeds from these resales; it may receive nominal proceeds (approximately $40.00) only if the Pre-Funded Warrants are exercised for cash at $0.0001 per share. The shares registered may be sold in public or private transactions at prevailing or negotiated prices; timing and amounts of any sales are determined by the selling stockholders.